397-62-6

Usage

Uses

Used in Pharmaceutical Development:
4-[(3-fluorophenyl)methylene]-2-phenyloxazol-5(4H)-one is utilized as a key intermediate in the synthesis of pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis Research:
In the field of organic synthesis, 4-[(3-fluorophenyl)methylene]-2-phenyloxazol-5(4H)-one serves as a valuable compound for studying reaction mechanisms and exploring novel synthetic pathways. Its reactivity and structural features make it an interesting subject for research.
Used in Material Science:
Due to its structural and functional properties, 4-[(3-fluorophenyl)methylene]-2-phenyloxazol-5(4H)-one may also find applications in material science. It could be used in the development of new materials with specific properties, such as improved stability or reactivity.
Used in Medicinal Chemistry:
In medicinal chemistry, 4-[(3-fluorophenyl)methylene]-2-phenyloxazol-5(4H)-one is employed as a building block for designing and optimizing drug candidates. Its unique chemical features can contribute to the discovery of new therapeutic agents with enhanced efficacy and selectivity.

InChI:InChI=1/C16H10FNO2/c17-13-8-4-5-11(9-13)10-14-16(19)20-15(18-14)12-6-2-1-3-7-12/h1-10H/b14-10+

Upstream product

• 495-69-2 Hippuric Acid 
• 456-48-4 3-Fluorobenzaldehyde 
• 98-88-4 benzoyl chloride 
• 1199-01-5 2-phenylazlactone 

Relevant academic research and scientific papers

Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents

As a continuation of our previous work, a series of new phenyl acrylamide derivatives (4Aa-g, 4Ba-t, 5 and 6a-c) were designed and synthesized as non-nucleoside anti-HBV agents. Among them, compound 4Bs could potently inhibit HBV DNA replication in wild-type and lamivudine (3TC)/entecavir resistant HBV mutant strains with IC50 values of 0.19 and 0.18 μM, respectively. Notably, the selective index value of 4Bs was above 526, indicating the favorable safety profile. Interestingly, unlike nucleoside analogue 3TC, 4Bs could significantly inhibit 3.5 kb pgRNA expression. Molecular docking study revealed that 4Bs could fit well into the dimer-dimer interface of HBV core protein by hydrophobic, π–π and H-bond interactions. Considering the potent anti-HBV activity, low toxicity and diverse anti-HBV mechanism from that of nucleoside anti-HBV agent 3TC, compound 4Bs might be a promising lead to develop novel non-nucleoside anti-HBV therapeutic agents, and warranted further investigation.

Base Induced Condensation of Malononitrile with Erlenmeyer Azlactones: An Unexpected Synthesis of Multi-Substituted Δ2-Pyrrolines and Their Cytotoxicity

An efficient, metal free approach to synthesize multi-substituted Δ2-pyrroline derivatives by mild base catalyzed cyclocondensation of malononitrile with Erlenmeyer azlactones via 1,2 addition was developed. The modularity of this reaction was used to assemble a range of poly-substituted pyrrolines. Further, synthesized products were screened for cytotoxic properties on different cancer cell lines such as A549 (Human lung adenocarcinoma cells), HeLa (Human cervical adenocarcinoma cells), Jurkat (Human chronic myeloid leukemia cells) and K562 (Human leukemic T cell Lymphoblast cells). Among the synthesized library of compounds, 6f and 6q displayed potent cytotoxic activity.

A simple and efficient method for the synthesis of Erlenmeyer azlactones

We have recently developed a novel and efficient method for synthesising Erlenmeyer azlactones under mild and rapid conditions. The reaction is performed by reacting 2-phenyl-5-oxazolone with an aldehyde in dichloromethane using alumina as a catalyst. The materials react instantly at room temperature, negating the need for high temperatures and long reaction times. We have successfully used this method for both aliphatic, aromatic and heteroaromatic aldehydes, synthesising previously unmade Erlenmeyer azlactones in moderate to high yields.